These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35182548)

  • 21. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
    Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
    Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab.
    Mizuno M; Horiguchi G; Teramukai S; Ichiyama S; Ito M; Hoashi T; Kanda N; Saeki H
    Australas J Dermatol; 2021 Nov; 62(4):e504-e509. PubMed ID: 34523731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters.
    Bakker DS; de Graaf M; Nierkens S; Delemarre EM; Knol E; van Wijk F; de Bruin-Weller MS; Drylewicz J; Thijs JL
    J Allergy Clin Immunol; 2022 Jan; 149(1):125-134. PubMed ID: 34237306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

  • 26. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Transcriptomic Classifier Model Identifies High-Risk Endotypes in a Prospective Study of Sepsis in Uganda.
    Cummings MJ; Bakamutumaho B; Tomoiaga AS; Owor N; Jain K; Price A; Kayiwa J; Namulondo J; Byaruhanga T; Muwanga M; Nsereko C; Nayiga I; Kyebambe S; Sameroff S; Che X; Lutwama JJ; Lipkin WI; O'Donnell MR
    Crit Care Med; 2024 Mar; 52(3):475-482. PubMed ID: 37548511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dupilumab for the Treatment of Atopic Dermatitis.
    Ferreira S; Torres T
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Machine learning applied to atopic dermatitis transcriptome reveals distinct therapy-dependent modification of the keratinocyte immunophenotype.
    Clayton K; Vallejo A; Sirvent S; Davies J; Porter G; Reading IC; Lim F; Ardern-Jones MR; Polak ME
    Br J Dermatol; 2021 May; 184(5):913-922. PubMed ID: 32730675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes.
    DiNardo AR; Gandhi T; Heyckendorf J; Grimm SL; Rajapakshe K; Nishiguchi T; Reimann M; Kirchner HL; Kahari J; Dlamini Q; Lange C; Goldmann T; Marwitz S; ; Abhimanyu ; Cirillo JD; Kaufmann SHE; Netea MG; van Crevel R; Mandalakas AM; Coarfa C
    Eur Respir J; 2022 Sep; 60(3):. PubMed ID: 35169026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling.
    Ewald DA; Noda S; Oliva M; Litman T; Nakajima S; Li X; Xu H; Workman CT; Scheipers P; Svitacheva N; Labuda T; Krueger JG; Suárez-Fariñas M; Kabashima K; Guttman-Yassky E
    J Allergy Clin Immunol; 2017 Feb; 139(2):562-571. PubMed ID: 27702671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multifaceted analysis of cross-tissue transcriptomes reveals phenotype-endotype associations in atopic dermatitis.
    Sekita A; Kawasaki H; Fukushima-Nomura A; Yashiro K; Tanese K; Toshima S; Ashizaki K; Miyai T; Yazaki J; Kobayashi A; Namba S; Naito T; Wang QS; Kawakami E; Seita J; Ohara O; Sakurada K; Okada Y; Amagai M; Koseki H
    Nat Commun; 2023 Oct; 14(1):6133. PubMed ID: 37783685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
    D'Erme AM; Romanelli M; Chiricozzi A
    Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.
    Khattri S; Brunner PM; Garcet S; Finney R; Cohen SR; Oliva M; Dutt R; Fuentes-Duculan J; Zheng X; Li X; Bonifacio KM; Kunjravia N; Coats I; Cueto I; Gilleaudeau P; Sullivan-Whalen M; Suárez-Fariñas M; Krueger JG; Guttman-Yassky E
    Exp Dermatol; 2017 Jan; 26(1):28-35. PubMed ID: 27304428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.
    Zimmermann M; Rind D; Chapman R; Kumar V; Kahn S; Carlson J
    J Drugs Dermatol; 2018 Jul; 17(7):750-756. PubMed ID: 30005097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting sepsis severity at first clinical presentation: The role of endotypes and mechanistic signatures.
    Baghela A; Pena OM; Lee AH; Baquir B; Falsafi R; An A; Farmer SW; Hurlburt A; Mondragon-Cardona A; Rivera JD; Baker A; Trahtemberg U; Shojaei M; Jimenez-Canizales CE; Dos Santos CC; Tang B; Bouma HR; Cohen Freue GV; Hancock REW
    EBioMedicine; 2022 Jan; 75():103776. PubMed ID: 35027333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
    Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
    J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis.
    Maintz L; Welchowski T; Herrmann N; Brauer J; Traidl-Hoffmann C; Havenith R; Müller S; Rhyner C; Dreher A; Schmid M; Bieber T;
    Allergy; 2023 Jan; ():. PubMed ID: 36647778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.